Paying For Placebo Is ‘Biggest Change’ In Medicare CED Policy, Official Says
This article was originally published in The Gray Sheet
Executive Summary
The director of Medicare’s coverage group sees the ability to pay physicians for providing a placebo or sham control in studies required under a coverage-with-evidence-development determination as a major improvement included in the agency's its recent guidance for CED.